Respiratory Medicine Case Reports最新文献_第7页

Safety and efficacy of osimertinib 160 mg daily given concurrently with a strong CYP3A4 inducer 奥希替尼每天160毫克与强CYP3A4诱导剂同时服用的安全性和有效性

IF 0.8

Respiratory Medicine Case Reports Pub Date : 2025-01-01 DOI: 10.1016/j.rmcr.2025.102200

Mostafa Aglan , Erin Spyropoulous , Joel Oster , Paul J. Hesketh , A.J. Piper-Vallillo

{"title":"Safety and efficacy of osimertinib 160 mg daily given concurrently with a strong CYP3A4 inducer","authors":"Mostafa Aglan , Erin Spyropoulous , Joel Oster , Paul J. Hesketh , A.J. Piper-Vallillo","doi":"10.1016/j.rmcr.2025.102200","DOIUrl":"10.1016/j.rmcr.2025.102200","url":null,"abstract":"<div><h3>Introduction</h3><div>Osimertinib remains the standard first-line therapy for patients with advanced <em>EGFR</em>-mutant NSCLC, at least in part due to its improved CNS penetrance compared to earlier generation EGFR TKIs. Strong CYP3A4-inducing medications are known to reduce the effective concentration of osimertinib, prompting the recommendation to double the standard osimertinib dose from 80 to 160 mg daily. However, little is known about the real-world safety and efficacy of osimertinib given in combination with long term CYP3A4 inducer use. We detail, to our knowledge, the first reported case of a patient receiving an escalated osimertinib dosage concurrent with a potent CYP3A4 inducer.</div></div><div><h3>Case presentation</h3><div>A 69-year-old-female with a long-standing history of a seizure disorder was diagnosed with stage IV EGFR exon 19 deletion positive lung adenocarcinoma. After a failed trial to wean the patient off phenytoin, osimertinib at a dose of 160 mg in combination with phenytoin was recommended based on existing clinical guidelines. She achieved a partial response and continues with stable disease for more than 32 months from initiation of osimertinib. Additionally, she tolerated osimertinib well with minimal side effects although with persistent dyspnea of unclear etiology.</div></div><div><h3>Conclusion</h3><div>Our case illustrates that 160 mg of osimertinib administered concurrently with a strong CYP3A4 inducer can be given safely and with retained efficacy in treating CNS metastatic EGFR-positive non-small cell lung cancer.</div></div>","PeriodicalId":51565,"journal":{"name":"Respiratory Medicine Case Reports","volume":"55 ","pages":"Article 102200"},"PeriodicalIF":0.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143800471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diagnostic challenges in pulmonary Langerhans cell histiocytosis: A case report of nodular presentation in an adult 肺朗格汉斯细胞组织细胞增多症的诊断挑战：1例成人结节表现

IF 0.8

Respiratory Medicine Case Reports Pub Date : 2025-01-01 DOI: 10.1016/j.rmcr.2025.102245

Nouman Aziz , Waseem Nabi , Sukhrob Makhkamov , Sadhna Kumari , Dimitri Chepkunov , Daye Chung , Sonu Sahni

引用次数: 0

From incidental findings to diagnosis: Adult presentation of asymptomatic congenital lobar emphysema 从偶然发现到诊断：成人无症状先天性肺气肿的表现

IF 0.8

Respiratory Medicine Case Reports Pub Date : 2025-01-01 DOI: 10.1016/j.rmcr.2025.102231

Reza jalli , Mohammad Javad Fallahi , Seyed Sina Dehghani

引用次数: 0

Acute exacerbation of interstitial lung disease in a patient with chronic inflammatory demyelinating polyradiculoneuropathy: A case report 慢性炎症性脱髓鞘性多神经根神经病患者间质性肺病急性加重1例报告

IF 0.7

Respiratory Medicine Case Reports Pub Date : 2025-01-01 DOI: 10.1016/j.rmcr.2025.102295

Koharu Harada , Takunori Ogawa , Ryosuke Nagaoka, Akihiko Kawana, Yoshifumi Kimizuka

引用次数: 0

A young female with multiple cavitary lung lesions 一名年轻女性肺部多腔性病变

IF 0.8

Respiratory Medicine Case Reports Pub Date : 2025-01-01 DOI: 10.1016/j.rmcr.2025.102182

Amina Pervaiz , Sharad Oli , Waed Alkaram , Shefali Godara , Suzanne M. Jacques , Khaled Alshabani

{"title":"A young female with multiple cavitary lung lesions","authors":"Amina Pervaiz , Sharad Oli , Waed Alkaram , Shefali Godara , Suzanne M. Jacques , Khaled Alshabani","doi":"10.1016/j.rmcr.2025.102182","DOIUrl":"10.1016/j.rmcr.2025.102182","url":null,"abstract":"<div><div>A 21-year-old female with a history of HPV and recurrent laryngeal papillomatosis has required frequent removal of laryngeal papilloma through direct laryngoscopy and has been treated with interferon alpha since she was 7 months old. She now presented with worsening dyspnea, hemoptysis, night sweats and significant weight loss. Infectious work up was negative. CT thorax showed significantly increasing right lower lobe mass with thick septation, debris and fluid concerning for malignant transformation. CT-guided biopsy of the mass showed features concerning for necrotic squamous cell carcinoma (SCC). Multidisciplinary tumor board classified this as malignant transformation due to bilateral lungs involvement and aggressive nature of the disease and recommended treatment with combination of chemotherapy and immunotherapy. Unfortunately, she continued to have declining performance status with multiple hospitalizations for hypoxic respiratory failure. Repeat CT scan of the chest showed progression of the lung lesions with extensive mediastinal involvement. She was unable to tolerate any additional therapy and decided with her family to pursue inpatient hospice. Malignant transformation into squamous cell carcinoma in recurrent respiratory papillomatosis is rare and is associated with worse outcomes.</div></div>","PeriodicalId":51565,"journal":{"name":"Respiratory Medicine Case Reports","volume":"55 ","pages":"Article 102182"},"PeriodicalIF":0.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143685861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reduced tracheal stenosing effect of nintedanib in a patient with scarred posttraumatic tracheal stenosis and airflow limitation - a case report 尼达尼布对创伤后瘢痕气管狭窄和气流受限患者的气管狭窄效果降低- 1例报告

IF 0.8

Respiratory Medicine Case Reports Pub Date : 2025-01-01 DOI: 10.1016/j.rmcr.2025.102168

Stefanie Klampfleitner , Andreas Fertl , Ositha Prinz , Martin Doerfler-Schalm , Dieter Munker , Markus O. Henke

{"title":"Reduced tracheal stenosing effect of nintedanib in a patient with scarred posttraumatic tracheal stenosis and airflow limitation - a case report","authors":"Stefanie Klampfleitner , Andreas Fertl , Ositha Prinz , Martin Doerfler-Schalm , Dieter Munker , Markus O. Henke","doi":"10.1016/j.rmcr.2025.102168","DOIUrl":"10.1016/j.rmcr.2025.102168","url":null,"abstract":"<div><h3>Introduction</h3><div>Nintedanib is a tyrosine kinase inhibitor and has been approved for the treatment of idiopathic pulmonary fibrosis (IPF) since 2020. In Clinical trials, the antifibrotic effect of nintedanib was shown.</div></div><div><h3>Case</h3><div>A 60-year-old female medical assistant, infected with COVID-19 in 10/2020, experienced a complicated course of disease leading to tracheal stenosis. Various interventions, including stent placements and tracheal surgeries, were performed. Due to recurrent restenosis, the patient was treated with nintedanib, a tyrosine kinase inhibitor used in idiopathic pulmonary fibrosis. The treatment spanned 306 days, during which the patient showed stability in pulmonary function. Nintedanib demonstrated a potential anti-inflammatory effect, reducing the frequency of interventions and prolonging stent-free intervals. The results suggest possible efficacy of nintedanib in managing scar-related granulation tissue, highlighting its potential in treating tracheal stenosis.</div></div><div><h3>Conclusion</h3><div>This case shows a decreased need for interventions, and the longer duration of stent placement may suggest a potential role for nintedanib in diminishing hypertrophic scarring, possibly through an anti-inflammatory effect. Further exploration of this potential in additional clinical trials would be valuable.</div></div>","PeriodicalId":51565,"journal":{"name":"Respiratory Medicine Case Reports","volume":"54 ","pages":"Article 102168"},"PeriodicalIF":0.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143349529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recurrent “transient ischemic attacks” caused by pulmonary arteriovenous malformation 由肺动静脉畸形引起的复发性“短暂性脑缺血发作”

IF 0.8

Respiratory Medicine Case Reports Pub Date : 2025-01-01 DOI: 10.1016/j.rmcr.2025.102172

Jorrit B.A. Welling , Mascha Schuurmans , T. David Koster

引用次数: 0

Klinefelter syndrome diagnosed at autopsy and small-cell lung carcinoma 尸检诊断为克氏综合征和小细胞肺癌

IF 0.8

Respiratory Medicine Case Reports Pub Date : 2025-01-01 DOI: 10.1016/j.rmcr.2025.102166

Haruyasu Sakuranaka , Ryoma Tanaka , Yuji Yamakawa , Shiho Yamada , Komei Igei , Yasuo Asai

引用次数: 0

Arduous management in treatment of elderly patient with pulmonary arterial hypertension and cardiopulmonary comorbidities 老年肺动脉高压合并心肺合并症的治疗管理艰苦

IF 0.8

Respiratory Medicine Case Reports Pub Date : 2025-01-01 DOI: 10.1016/j.rmcr.2025.102174

Yu Enomoto , Kei Kusaka , Kengo Sato , Keita Takeda , Masahiro Kawashima , Yoshiteru Morio

引用次数: 0

Successful stent removal after chemoradiotherapy followed by durvalumab for locally advanced non-small cell lung cancer with airway stenosis: A report of three cases 局部晚期非小细胞肺癌伴气道狭窄，放化疗加杜伐单抗后支架摘除成功：附3例报告

IF 0.8

Respiratory Medicine Case Reports Pub Date : 2025-01-01 DOI: 10.1016/j.rmcr.2025.102217

Yuki Takigawa , Ken Sato , Daisuke Minami , Kenichiro Kudo , Shoichiro Matsumoto , Miho Fujiwara , Takeru Ichikawa , Tomoyoshi Inoue , Suzuka Matsuoka , Hiromi Watanabe , Akiko Sato , Hiroyasu Shoda , Nobuhisa Ishikawa , Keiichi Fujiwara , Takuo Shibayama

引用次数: 0